

ACS5 / ACSL5 Antibody (C-Terminus) Goat Polyclonal Antibody

Catalog # ALS12456

# Specification

# ACS5 / ACSL5 Antibody (C-Terminus) - Product Information

Application Primary Accession Reactivity Host Clonality Calculated MW Dilution WB, IHC-P, E <u>O9ULC5</u> Human, Monkey Goat Polyclonal 76kDa KDa WB~~1:1000 IHC-P~~N/A E~~N/A

# ACS5 / ACSL5 Antibody (C-Terminus) - Additional Information

Gene ID 51703

Other Names Long-chain-fatty-acid--CoA ligase 5, 6.2.1.3, Long-chain acyl-CoA synthetase 5, LACS 5, ACSL5, ACS5, FACL5

**Target/Specificity** Human ACSL5. This antibody is expected to recognise isoform a (NP\_057318.2) and isoform b (NP\_976313.1 and NP\_976314.1).

**Reconstitution & Storage** Store at -20°C. Minimize freezing and thawing.

**Precautions** ACS5 / ACSL5 Antibody (C-Terminus) is for research use only and not for use in diagnostic or therapeutic procedures.

# ACS5 / ACSL5 Antibody (C-Terminus) - Protein Information

Name ACSL5 (<u>HGNC:16526</u>)

#### Function

Catalyzes the conversion of long-chain fatty acids to their active form acyl-CoAs for both synthesis of cellular lipids, and degradation via beta-oxidation (PubMed:<a

href="http://www.uniprot.org/citations/17681178" target="\_blank">17681178</a>, PubMed:<a
href="http://www.uniprot.org/citations/22633490" target="\_blank">22633490</a>, PubMed:<a
href="http://www.uniprot.org/citations/24269233" target="\_blank">24269233</a>, PubMed:<a
href="http://www.uniprot.org/citations/33191500" target="\_blank">33191500</a>, PubMed:<a
href="http://www.uniprot.org/citations/33191500" target="\_blank">33191500</a>, PubMed:<a
href="http://www.uniprot.org/citations/33191500" target="\_blank">33191500</a>, PubMed:<a
href="http://www.uniprot.org/citations/33191500" target="\_blank">33191500</a>, PubMed:<a
href="http://www.uniprot.org/citations/33191500" target="\_blank">33191500</a>). ACSL5 may
activate fatty acids from exogenous sources for the synthesis of triacylglycerol destined for
intracellular storage (By similarity). Utilizes a wide range of saturated fatty acids with a preference



for C16-C18 unsaturated fatty acids (By similarity). It was suggested that it may also stimulate fatty acid oxidation (By similarity). At the villus tip of the crypt- villus axis of the small intestine may sensitize epithelial cells to apoptosis specifically triggered by the death ligand TRAIL. May have a role in the survival of glioma cells.

**Cellular Location** 

Mitochondrion. Endoplasmic reticulum. Mitochondrion outer membrane; Single-pass type III membrane protein Endoplasmic reticulum membrane; Single-pass type III membrane protein. Cell membrane

### ACS5 / ACSL5 Antibody (C-Terminus) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- <u>Western Blot</u>
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- <u>Cell Culture</u>

### ACS5 / ACSL5 Antibody (C-Terminus) - Images



Anti-ACSL5 antibody IHC of human small intestine.

# ACS5 / ACSL5 Antibody (C-Terminus) - Background

Acyl-CoA synthetases (ACSL) activate long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. ACSL5 may activate fatty acids from exogenous sources for the synthesis of triacylglycerol destined for intracellular storage (By similarity). Utilizes a wide range of saturated fatty acids with a preference for C16-C18 unsaturated fatty acids (By similarity). It was suggested that it may also stimulate fatty acid oxidation (By similarity). At the villus tip of the crypt-villus axis of the small intestine may sensitize epithelial cells to apoptosis specifically triggered by the death ligand TRAIL. May have a role in the survival of glioma cells.

#### ACS5 / ACSL5 Antibody (C-Terminus) - References

Gassler N., et al.Gastroenterology 133:587-598(2007). Clark H.F., et al.Genome Res. 13:2265-2270(2003).



Ota T., et al.Nat. Genet. 36:40-45(2004). Suzuki Y., et al.Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases. Deloukas P., et al.Nature 429:375-381(2004).